Introduction
============

Glaucoma is the principal cause of optic nerve degeneration and the second leading cause of blindness worldwide. The disease is predicted to affect more than 50 million people including more than 3 million people in the United States by the year 2020 \[[@r1],[@r2]\]. All forms of glaucoma are characterized by a loss of retinal ganglion cells, leading to optic nerve degeneration and corresponding visual field defects \[[@r3]\]. Unless the disease is identified and therapeutic intervention is begun at an early stage, individuals with glaucoma develop irreversible blindness. Primary open-angle glaucoma (POAG; OMIM [137760](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=137760)) is the most common form of glaucoma and is associated with an open chamber angle and normal-appearing trabecular meshwork. The prevalence of POAG is low in persons under the age of 50 but increases significantly after the age of 70 \[[@r4]-[@r6]\]. Juvenile open-angle glaucoma (JOAG) is a rarer subset of POAG that develops before the age of 40 \[[@r7]\].

A family history of glaucoma is widely recognized as a major risk factor for the disease, suggesting that specific gene defects contribute to the pathogenesis \[[@r8]\]. Indeed, both Mendelian and non-Mendelian forms of inheritance have been described; the more common adult-onset form of POAG has heritability consistent with that of a complex trait while JOAG exhibits autosomal dominant inheritance \[[@r9],[@r10]\].

Linkage approaches using large pedigrees affected by POAG have lead to the identification of 14 major genetic loci for adult-onset POAG (GLC1A-GLC1N) \[[@r11]-[@r14]\] and three genes that contribute to POAG have been identified. Myocilin (*MYOC*, GLC1A, OMIM [601652](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601652)) is responsible for 20% of patients with JOAG \[[@r15]\] and 3%--5% of POAG, optineurin (*OPTN*, GLC1E, OMIM [602432](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602432)) \[[@r16]\] is primarily associated with low tension glaucoma, and WD repeat domain 36 (*WDR36*, GLC1G, OMIM [609669](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=609669)) \[[@r17]\] may be a modifying factor that can influence the severity of disease \[[@r18]\]. None of the disease-associated DNA sequence variants in any of these genes are responsible for a significant fraction of the disease in the POAG population \[[@r16]-[@r25]\]. These results highlight the multifactorial inheritance of POAG and point to the existence of additional loci and genes that can contribute to this complex disease \[[@r10],[@r11]\].

Six of the open-angle glaucoma loci are primarily associated with early onset open-angle glaucoma or JOAG: GLC1A, GLC1J, GLC1K, GLC1M, GLC1N, and a novel region on 2p15--16 that partially overlaps with GLC1H \[[@r12],[@r13],[@r15],[@r26]-[@r28]\]. We previously performed a genome-wide scan using 25 JOAG families that identified two novel JOAG loci on 9q22 (GLC1J) and 20p12 (GLC1K) \[[@r26]\]. In our previous study, haplotype analysis of 15 families identified seven families with consistent linkage to the GLC1J region, five families with consistent linkage to the GLC1K region, and three families with consistent linkage to both regions. Recombination events identified a 9 cM region on chromosome 9 between markers D9S1841 and D9S271 (GLC1J) and a 46 cM region on chromosome 20 between markers D20S846 and D20S891 (GLC1K). The purpose of the current study is to saturate the GLC1K region with single nucleotide polymorphism (SNP) markers making further definition of the boundaries of the critical recombinant region possible and to screen candidate genes located in the refined region for biologically significant mutations.

Methods
=======

Families
--------

This study adhered to the tenets of the Declaration of Helsinki and has been reviewed and approved by the Institutional Review Board of the Massachusetts Eye and Ear Infirmary. Four JOAG families (44 individuals) with previously demonstrated linkage to GLC1K were used for this study. All of these families demonstrated inheritance patterns consistent with autosomal dominant inheritance and had sufficient size and structure that haplotype analysis could be performed using all four of the original parental chromosomes. All of the sampled family members (affected and unaffected) who entered into this study underwent a complete ocular examination including gonioscopy, tonometry, and fundoscopy. All affected individuals also had visual field testing using the automated Humphrey perimeter. Affected individuals met the following three criteria: 1) intraocular pressure measured by applanation tonometry in both eyes was greater than 22 mmHg or greater than 19 mmHg on two glaucoma medications, 2) there was glaucomatous optic neuropathy in both eyes, and 3) visual field loss was consistent with optic nerve damage in at least one eye. Juvenile open-angle glaucoma (JOAG) is defined as patients who meet these criteria and have an age of onset before the age of 40 while adult onset primary open-angle glaucoma patients meet the above criteria and have an age of onset after the age of 40 \[[@r7]\]. Glaucomatous optic neuropathy was defined as a cup to disk ratio higher than 0.7 or focal loss of the nerve fiber layer associated with a visual field defect. The affected family members had normal appearing angle structures on gonioscopy, and none of the affected family members had any evidence of secondary glaucomas including pigment dispersion, anterior segment dysgenesis, and corneal abnormalities.

Genotyping
----------

Genomic DNA was prepared from blood samples from family members using previously described techniques \[[@r18]\]. SNP genotyping was performed using a quantitative polymerase chain reaction (PCR) approach (TaqMan Assay; Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. The reverse transcription polymerase chain reaction (RT--PCR) amplification of genomic DNA was performed in a 96 well plate with a sequence detection system (ABI Prism©7000 Sequence Detection System; Applied Biosystems Inc., Foster City, CA). The thermal cycler (model 2720, Applied Biosystems Inc., Foster City, CA) was set at the following parameters: 50 °C for 2 min, 95 °C for 10 min, 92 °C for 15 s, and 58 °C for 1 min for a total of 60 cycles. Microsatellite genotypes had been previously obtained \[[@r26]\].

Haplotype analysis
------------------

Forty SNPs with minor allele frequency greater than 40% were chosen at approximately 100,000 base pair intervals throughout the previously defined GLC1K region \[[@r29]\]. Alleles from informative SNP markers were added to previously established microsatellite-based haplotypes \[[@r26]\]. Haplotypes were deduced initially using the [Simwalk 2](http://www.genetics.ucla.edu/software/simwalk) program \[[@r30]\]. These haplotypes were confirmed by visual inspection, and ambiguities in transmission were resolved where possible.

DNA sequencing
--------------

All exons and 100 base pairs of the flanking intron sequence were sequenced for bone morphogenetic protein 2 (*BMP2*); phospholipase C beta 1 (*PLCB1*); phospholipase C beta 4 (*PLCB4*); and BTB POZ domain containing 3 (*BTBD3*) using nested PCR strategies for amplification. Oligonucleotides for amplification and sequencing were selected using [Primer3](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) software (provided by Massachusetts Institute of Technology, Cambridge, MA) and were located at least 40 bp from each exon's splice site. Primer sequences are presented in [Table 1](#t1){ref-type="table"}. PCR was performed in a thermal cycler in a total volume of 25 μl containing 50 ng genomic DNA; 1.5 mM MgCl~2~; 200 μM each of dATP, dCTP, dGTP, and dTTP; 100 ng forward PCR primer, 100 ng reverse PCR primer; 20 mM Tris-HCl (pH 8.4); 50 mM KCl; and 0.5 U Taq DNA polymerase (Platinum Taq; Invitrogen-Life Technologies, Rockville, MD). Cycling conditions were as follows: an initial denaturing step of 5 min at 94 °C; 35 cycles of denaturation (94 °C for 45 s), annealing (primer-specific annealing temperature for 60 s), elongation (72 °C for 45 s), and a final elongation step of 5 min at 72 °C. Amplified genomic DNA was directly sequenced using sequencing chemistries (BIGDYE version 3.1; Applied Biosystems Inc.) and an automated sequencer (model 3100; Applied Biosystems Inc.). Sequences were analyzed using sequencer software (Gene Codes Corp., Ann Arbor, MI) and compared to the gene sequence in the [public database](http://genome.ucsc.edu/) \[[@r31],[@r32]\].

###### Oligonucleotide primers.

  **Gene**   **Exon**   **Forward primer**           **Reverse primer**           **Sequence primer**
  ---------- ---------- ---------------------------- ---------------------------- ----------------------
  *BMP2*     1A         ggaacttgggacccttcatt         agtgcctgcgatacaggtct         ttgagcttcggtcggtctta
             1B         cttctagcgttgctgcttcc         ccaccacacaagcagtgagt         tcctgagcgagttcgagttg
             2A         atcaaatcccacgatgaggt         cacttccaccacgaatccat         tcaaacgtcattacttggct
             2B         aaacctgcaacagccaactc         ctcgtcaaggtacagcatcg         ggtgaatcagaatgcaagca
             2C         gagacaccctttgtacgtgga        tacttcatgtgctggggttg         atcatctgaactccactaat
  *PLCB1*    1          ggcttctcttcgccttcc           agtgcgcccattgcataac          tccggagcagagaaaggagc
             2          ggaaagaacctcagttacataatgg    gactttgaaacgtcctaagtcct      tgactactttggagaatctg
             3          tgatttaggaatggcttgtagga      gggcatactggctattgtgtt        cttcagtcaagtctcaagat
             4          tacctctgggcaagttgctt         gcacttatacttggcagctgaa       cattctaactcaacagaagt
             5          aaagaacatctcctttggaaaa       gtgcagcttggaggaaagag         gaactaatgtgtcttcctgg
             6          ggcttctggaatgctgctaa         gcatttccacactcccactt         ttaatctgggtgccaactgt
             7          atgcaaatgcatggaggaa          ttcctctccgatgataatcca        tgagttggcatcatctgtta
             8          ccctaaagccagtgtccaaa         gggcaagattgtgtgatcct         acgctacggttgacctcata
             9          cggtagcaattgcacaagat         ccgaaaggaatgccttgtaa         aggtatagaaattatggtgg
             10         atttggtggggctcatgtaa         agagttctcagaggcacttcg        taccttggacactacaagat
             11         aaattgagccattaccttctgg       gcctctgaaattgcaaagatg        taactgctgcagctcttaga
             12         tccagaatcaagagtcagaattagc    gatcctacaagtccaacggataa      gatacaattctctgaatgga
             13         ttcgctgtccatctgtgtatg        caccaactgcattaatcttacca      agttaagataaagatccagg
             14A        ttgggtttctatgttccattg        ttccttctgatgacttgtgtga       tatggtcttcttcatgtaga
             14B        tgagcagtgttgaaggtaggg        ggatggtctcgaactcctga         tagctggaatctggagttcc
             15         tgttttcaatgccacgtgtt         tcttctccggattgtggaac         cttccaaggaaatctgtaat
             16         aggtgttgctgttgcctttc         tgtgtaaagtaacaaggcagtcaa     tctgcatgcttgaatcatgt
             17         tctgacccaagtagcaaacg         acacagagcttggtggtgtg         cctcaacttcactgaatatt
             18         tatcccaaagtagcccaacg         ttcccttcattgaaatttgctt       ggtagcttcttagttactat
             19         tctgtgtttcctgcatttctaca      gagaacacacggacccctta         aagtggactgggatcaactt
             20         tgggtgaggacatagaacca         ccgtccatttgaggcatact         ttgctgaagagcatttgtgg
             21         caagatcacgccactgcac          ctaaatctcatcgcccttgtt        gtcctgattgaataatacct
             22         tgacatgtgatttggaattatcttt    cgaaagtaggggtgattctga        atcacatagatgcgcataat
             23         aatgactgggtggatggatg         tgctattccttctcccaagg         atggtcagatagatgagtaa
             24         cgggcatagacataggttgg         ggagctcctcctaagtccaca        tggctcaacactatgctgtt
             25         actgcacctggcctaatgtt         ttttatgccagtagggttctagc      agagatttagattcaaggcc
             26         cccaggtagagctgacatcaa        aaagctatggagaacggaggt        ttgctcttaaactctagctg
             27         ttcagtctctgggattggaga        tctcaagttggtgccagtca         aggaattctggtgaataacc
             28/29      tggttctaaattgtcctcattgc      cacgaaggagtctttgactgg        catccatcacagatattcta
             30         gcaacagagcgaaaccttgt         gcaattcaacttgcagaaatgt       aatgttgagagttctgtaac
             31         agtgcagtccattgatcacc         caccaggtgatgataaatgctta      atgtaagccatagatctgaa
             32         cctctataggtgaccagtgaatga     cttctcgggaagatggtcct         gtatatctctttcagagagt
  *PLCB4*    1          cccaaatgatcacctctggt         gcctcttttcaacaactccaa        gcgaagtgattaaccatcct
             2          aacctatcctagagcaagatgtttt    gaggataatgtccttaatcatcactg   gtttagaagctcagcaatat
             3          gcactgccttcatcatcaga         gccttttattagggtctgcttg       agcagtttgcctgtatcata
             4          gaatgcaccactgttcacca         cccacaggagtgacatgcta         gaataatgctaggtgtctgg
             5          atggcacaatagatggcaca         gaggaaggaaccacctagcc         agatggctgtgtgacaggaa
             6          caaccctaaattcatcttatagcaca   tttgccacctattttgacca         taacagaattgaagctgctc
             7          ctaaccagctctgggaacca         agctggccttcatttccttt         tagtctcactctccatagta
             8          tagtgagatggcctggcagt         aaagttccaggtgctgcaat         gcaggaatcagagatgaaga
             9          gggagtgttttccttctgttg        gtgcaaagccaatgtgaaga         agaattcaccactacttcag
             10         ttaaggagaaaggcaggaagg        gtcatcaatccatggctcag         cagtgaggtcctatctttgt
             11         gacagatgaaagttcttgggaaa      caacgttaaatgaccatgataatcc    gctgcctcagcttccatgaa
             12         tgataataccaaccagatgaggaa     tgaaggcataatgcttgagaaa       ttaacctgtatatgccatga
             13         ccacagggaactcaaccttt         gtgcccttgctggagaatta         ccaggtctgaattgctggaa
             14         tctcacattagcattaagaggacaa    tgatgtaagctttccgtaccaa       gtgagaatctttaattgcct
             15         gctctgcacacctctggaa          tgtggcaatcttgctctgaa         gtttgcagcactagtctaag
             16         tcacgaggactgaacctcct         attatgggcttgagccactg         tgtcgatctcaaggcctagg
             17         ccttgacgttgaataggtaagagtt    tggccctgactaatgagtaattt      tactgcatatatcaatgtcc
             18         ctccttttgcattattcagagc       ccacataccaaggtggcttc         caacagacactaacttctta
             19         tctccatccacaggatgtca         gccatggtctttcccacata         gctactgacatgataatgta
             20         catggcagctgtgacaatct         ttgctttgccatatgtctgc         gaactgtgatcttaagcatc
             21         tgccttaaatagaccaagcaga       tcccagacataaaatcctcca        gcctaggagcaatctgatac
             22         ggcacattctcttccatcct         aagttgtgagcagcacatgg         agctcctgtgttacagatgg
             23         gaaggtagaacatctgcttgaaa      tgttgtcggttgaataagtgc        tgcctatagtagttgttcga
             24         tcttgggcactgtagctcat         ggcagcattagcaggaataga        ggaatgcagatggatcatgg
             25         agctgtgccttcctcagtgt         gccactgatgatgaagtggat        caggtatccaggattgtagt
             26         ctttccttggctggatcctt         acggcctgtccaggtaacta         gtatggtagaagtttactgg
             27         tgccctcaatcaatcacttg         tgcttcaagtaagcctttgg         tcgatgagatttcgatatgt
             28         aaggatagaagacttaaagcagatga   gcactcccaaaccgattcta         ctcaccaagtgtaatcattg
             29         tgttgaatgggagatctgga         ccttgacctaaacagcagca         gtctgtactgttctcagatt
             30         aaagaccagtgttgcccaat         ccagatcagctgcaggctac         gagccatgacatctcatatt
             31         aacttcctgcttcccattga         tcagccatatgatgagatacacaa     tgattcaccaattaagttgg
             32         tgagaggagtgagcctagtca        gccacaagtgttttgctgtc         agtgcatgacattaagtaca
             33         tgaatcaggaagaatacacatgg      ggagcagagaagctggaatg         cttctctggacattatatgt
             34         ggtttagtcatgcgtaagtcctc      atatgcaagccactggtca          tagcaggaaagatcttccca
             35         taagaaggtcccaggcaatg         cagacattccaagtctctctgg       tagcaaggatgtggtgacag
  *BTBD3*    1A         caggaatcatgatggggata         gcaacttgctgctgttgcta         tcagttaacctcttagcccg
             1B         tgatgcttccagagacggta         gcttctgggaaaagaggaaa         gcagcaagttgccaccagtt
             2          cattcaagtgacagggttgtct       aaaattaagcgtggccaaag         tgccttgaagttactggact
             3          catggcaagctaccctgtgt         cccaaattctacgtcaaggtg        gcagtagattttaggtacgc
             4A         gaggctagaatggtagcacaaag      acttcagcccagttgagagc         gaatgttcctttactctgca
             4B         ctgttcgaggagccagacct         cctgccgcttaagttcaatc         tgattgatgcccaggctgag
             4C         gtcaccgtttccagtcgtgt         aattaccggcactgatcaca         agcatccagtttgcagttga

Oligonucleotide primers used to PCR amplify each of the indicated exons of *BMP2*, *PLCB1*, *PLCB4*, and *BTBD3*, along with the primer sequence used to sequence each PCR product.

Results
=======

Reduction of the GLC1K critical interval
----------------------------------------

![*GLC1K* haplotype analysis in JOAG families. Haplotypes consisting of alleles for microsatellite repeat markers and SNPs are shown under each individual in the pedigrees. The boxed regions indicate the haplotype that segregates with the affected status. The small arrow identifies the location of a recombination event on the non-disease chromosome. The [UCSC genome browser](http://genome.ucsc.edu/) \[[@r27]\] was used to determine the location of the markers.](mv-v14-1319-f1){#f1}

###### DNA sequence variants in candidate genes located within the GLC1K refined region.

  **Gene (Mb)**                                                                           **Ocular expression**                                                   **Function**                                                        **Sequence variant**                                                                      **Family**        **Individual**
  --------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------- ----------------
  *BMP2* (6.7)                                                                            Lens, fetal eye                                                         Member of TGFB superfamily                                          c.1946 C\>T D387D [rs13037675](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=13037675)   JOAG-25           III-2
                                                                                          c.2220 A\>C 3′ UTR                                                      JOAG-52                                                             II-1                                                                                                        
  *PLCB1* (8.6)                                                                           Retina, fetal eye                                                       Intracellular transduction of extracellular signals                 c.105 C\>T D34D [rs16994453](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=16994453)     JOAG-25           III-2
  c.2085 C\>T G694G [rs3761170](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3761170)   JOAG-25                                                                 III-2                                                                                                                                                                           
  c.2202 A\>G V733V [rs8118206](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=8118206)   JOAG-52                                                                 II-1                                                                                                                                                                            
  c.2568 C\>T A855A [rs2076413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2076413)   JOAG-25                                                                 III-2                                                                                                                                                                           
  c.2991 A\>G A996A [rs2235613](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2235613)   JOAG-52                                                                 II-1                                                                                                                                                                            
  *PLCB4* (9.4)                                                                           Ciliary body, trabecular meshwork, retina, retinal pigment epithelium   Intracellular transduction of extracellular signals in the retina   c.197 A\>GA21T [rs6077510](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=6077510)        JOAG-52 JOAG-25   II-1, III-2
  *BTBD3* (11.6)                                                                          Retina, iris, fetal eye                                                 Protein--protein interaction; DNA binding protein                   c.909 G\>A A303A [rs35364034](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35364034)    JOAG-52           II-1
                                                                                          IVS2+12G\>A                                                             JOAG-52                                                             II-1                                                                                                        

The DNA sequence variants identified by genomic sequencing of all exons and flanking intron sequences are shown for each candidate gene. Expression data are from the [Stanford SOURCE database](http://source.stanford.edu).

The GLC1K region was previously identified as a glaucoma gene locus by a microsatellite-based genome scan using a population of 25 multi-generational JOAG pedigrees (overall multipoint LOD score of 4.0) \[[@r26]\]. Haplotypes that were based on the microsatellite repeat markers used in the scan identified key recombination events in affected members in pedigree JOAG-52, a three-generation family with sufficient size and structure to establish independent linkage to the GLC1K region (maximum LOD score=3.2). These recombination breakpoints defined a 46 cM region extending from marker D20S846 to marker D20S891 in affected individuals and a 23 cM region extending from marker D20894 to marker D20878 if unaffected individuals were included in the analysis. To reduce the size of the critical region, 40 SNPs (single nucleotide polymorphisms) with minor allele frequencies of at least 40% were selected at approximately 100 Kb intervals throughout the previously defined GLC1K region \[[@r29]\]. Fifteen SNPs were informative for haplotype analysis, and alleles from these SNPs were evaluated for segregation in all members of pedigree JOAG-52 ([Figure 1A](#f1){ref-type="fig"}). Haplotype analysis using the previous microsatellite alleles as well as the added SNP alleles identified recombination breakpoints that defined a new critical interval of 12.7 Mb, extending from marker D20S846 to marker [rs6081603](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=6081603), a reduction of approximately 26 Mb. The critical recombination events defining the 12.7 Mb region occurred in individuals II-1 and II-3, both affected. A third recombination event occurred in individual III-5 who is unaffected at age 45. This recombination event would reduce the size of the region to 9 Mb, extending from marker [rs1232605](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1232605) to marker [rs6081603](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=6081603). Because of the unknown penetrance of JOAG, we are using the most conservative measure for the size of the region of 12.7 Mb, which is based on the recombination events in individuals known to be affected.

To provide additional support for the new critical region, a selection of SNPs that defined the shared haplotype in JOAG-52 was evaluated in a group of smaller pedigrees ([Figure 1B,C](#f1){ref-type="fig"}) with previous microsatellite-based haplotypes consistent with linkage to GLC1K. The affected individuals in each family shared a different haplotype, and none of the affected individuals had recombination events that led to a further reduction in the size of the GLC1K critical region.

Evaluation of candidate genes located in the reduced GLC1K critical interval
----------------------------------------------------------------------------

The refined GLC1K locus lies within a gene-rich region on chromosome 20 that contains several genes that could be considered good candidates for early onset glaucoma based on their proposed function and tissue expression. Four of these genes, *BMP2*, *PLCB1*, *PLCB4*, and *BTBD3*, were selected for mutation screening. Bone morphogenetic proteins (BMPs) are multifunctional cytokines that have a broad spectrum of activities in various cell types and tissues. In retinal ganglion cells growing in culture, BMPs increased the number, length, and branch points of neurites, suggesting that BMPs function to promote and maintain ganglion cell growth \[[@r33]\]. Members of the BMP family have also been shown to be expressed in the human trabecular meshwork and optic nerve head \[[@r34]\]. *BMP2*, one member of the BMP family located within the critical region, was selected for screening because of the potential role of the protein in the development and function of both the trabecular meshwork and the retinal ganglion cells. *PLCB1* and *PLCB4* are also located within the newly defined critical region. PLCB1 has been implicated in trabecular meshwork function and has been shown to have reduced levels of expression in glaucomatous ciliary body cells grown in culture \[[@r35]\] while PLCB4 appears to function in the retinal visual response \[[@r36]\]. *BTBD3* is a member of the protein family that contains BTB/POZ domains. The BTB/POZ (broad complex Tramtrack bric-a-brac/Pox virus and zinc finger) domain is an evolutionarily conserved protein--protein interaction motif. Many BTB-containing proteins are transcriptional regulators involved in a wide range of developmental processes \[[@r37]\]. Several BTB/POZ homologs are involved in ocular development and retinal function. *Mri* is a drosophila homolog that was initially identified in a microarray screen for molecules that regulate retinal apoptosis, the process that retinal ganglion cells undergo in glaucoma \[[@r38]\]. Another BTB/POZ protein, Tramtrack69 (*Ttk69*), block neuronal photoreceptor differentiation when overexpressed \[[@r39]\]. The entire coding sequence of all four genes including 100 bases of the 5′ and 3′ untranslated regions and the flanking intron/exon boundaries was screened for DNA sequence variants by PCR amplification followed by direct genomic sequencing in an affected member of each family with linkage to GLC1K. Ten DNA sequence variants were detected, although none of these would be predicted to have significant biological consequences ([Table 2](#t2){ref-type="table"}). Studies to detect alterations of gene expression or evaluations of gene dosage were not carried out.

Discussion
==========

Previous studies using a collection of 25 JOAG pedigrees identified GLC1K as a juvenile-onset glaucoma locus. In the present study, using high density SNP markers and haplotype analysis, we have reduced the size of the GLC1K locus on chromosome 20 to 12.7 Mb, a reduction of over seventy percent. This reduction in size of the interval is based on recombination events in affected individuals only. If a recombination event in an unaffected individual (JOAG-52, individual III-5, age 45) is included, the size of the interval is reduced further to 9 Mb. Within the reduced region, we have screened four potential disease-causing candidate genes. Ten sequence variants were identified in JOAG-affected family members, although none of these are predicted to have a significant biological effect. Using a variety of databases ([Stanford Microarray Database](http://source.stanford.edu/cgi-bin/source/sourceSearch) \[[@r40]\], [UNIgene](http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene) \[[@r41]\], [NEIBank](http://neibank.nei.nih.gov/index.shtml) \[[@r42]\], and [UCSC genome browser](http://genome.ucsc.edu/) \[[@r31]\]), we have identified at least 30 genes within the refined GLC1K region, and of these genes, 24 have significant ocular expression. These genes will be prioritized for mutation screening according to the putative function of the gene product as well as tissue expression.

The improved localization of GLC1K has excluded several genes that would previously have been considered to be excellent candidates. These include a group of genes that could participate in the development of the ocular structures affected in glaucoma including *SOX12* (2.5 Mb), *EYA 2* (45 Mb), *Sall4* (49 Mb), and *VSX1* (25 Mb) \[[@r43]-[@r46]\]. The exclusion of *VSX1* is particularly interesting as mutations in this gene have been associated with some cases of posterior polymorphous dystrophy (PPMD), a condition that can be confused with primary juvenile open-angle glaucoma \[[@r46],[@r47]\]. One locus for the oculo-oto-dental syndrome, a developmental ocular syndrome that can involve the anterior segment of the eye, has been mapped to 20q13 with peak linkage to D20S836 (44.3 Mb) \[[@r48]\], a location that is distal to the telomeric boundary of the refined GLC1K region, thus excluding this locus from further consideration. The reduction in size of the GLC1K region will greatly increase the efficiency of screening the remaining candidate genes located within the refined critical region.

The identification and characterization of genes responsible for early onset primary open-angle glaucoma (JOAG) may help define molecular pathways that are responsible for open-angle glaucoma including the common adult-onset form of the disease. It is also possible that a gene that is responsible for juvenile onset primary open-angle glaucoma can also contribute to adult forms of the disease as has been shown for some mutations in the gene coding for myocilin \[[@r49]\]. Defining the molecular mechanisms responsible for glaucoma will lead to a better understanding of the underlying pathophysiology of the disease and will lead to novel methods of treatment and diagnosis for this blinding condition.
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